A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.

Also called NCT07931547

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07931547
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Brazil, China, Czechia, Germany, India, Japan, Poland, South Korea, Türkiye (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07931547. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
Acronym
AMBITION 2
Intervention (Other)
Placebo
Intervention (Drug)
Zenagamtide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07931547
Content hash
a8a1f6afc484315789432cac114d81dec53bcfbc6edda30fa0807d3b545ffff6